| Literature DB >> 21049213 |
Katia Coelho Ortega1, Josiane Lima de Gusmão, Angela Maria Geraldo Pierin, José Luiz Nishiura, Edna Caetano Ignez, Carlos Alexandre Segre, Carlucci Gualberto Ventura, Gisele Peixoto Mano, Viviane Fontes, Francisco Mogadouro da Cunha, Décio Mion.
Abstract
OBJECTIVES: To evaluate the importance of providing guidelines to patients via active telephone calls for blood pressure control and for preventing the discontinuation of treatment among hypertensive patients.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21049213 PMCID: PMC2974815 DOI: 10.1590/s1807-59322010000900008
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Study groups demographics.
| Uncomplicated n = 179 | Complicated n = 175 | Traditional n = 176 | Current n = 178 | No Phone Calls n = 246 | Phone Calls n = 108 | |
| Age (years) | 53±11 | 53±11 | 54±11 | 52±11 | 54±11 | 52±11 |
| Gender (%) | ||||||
| Male | 27 | 41 | 33 | 34 | 33 | 34 |
| Female | 73 | 59 | 67 | 66 | 67 | 66 |
| Skin color (%) | ||||||
| Whites | 62 | 52 | 60 | 54 | 56 | 60 |
| Non-whites | 38 | 48 | 40 | 46 | 44 | 40 |
| BMI (kg/m2) | 29±4 | 29±4 | 29±4 | 29±4 | 29±4 | 29±4 |
| Blood Pressure at Randomization (mmHg) | ||||||
| Systolic | 155±12 | 163±24 | 159±19 | 158±19 | 159±19 | 158±19 |
| Diastolic | 91±10 | 102±20 | 96±17 | 97±16 | 97±16 | 97±17 |
| Heart rate | 80±13 | 83±13 | 81±13 | 82±13 | 82±13 | 82±13 |
Data are shown as mean±s.d.; BMI = Body Mass Index; p>0.05: “complicated” vs. “uncomplicated”, “traditional” vs. “current”, “phone calls” vs. “no phone calls” for age, gender, skin color and BMI.
Blood pressure at randomization: uncomplicated vs. complicated groups: systolic – t = 3.78, p = 0.0002; diastolic – t = 6.44, p<0.000001; FC – t = 2.41, p = 0.016
Blood pressure (mmHg) at the beginning and end of the 12-month treatment in the “uncomplicated” and “complicated” groups, according to the “traditional” and “current” treatments and randomization into the “phone calls” and “no phone calls” groups.
| Group | Randomization Visit | Final Visit |
| Uncomplicated (n = 179) | 155±12/91±10 | 126±14*/73±11* |
| “Traditional” Treatment (n = 90) | 155±12/91±9 | 126±14*/71±11* |
| “Current” Treatment (n = 89) | 155±12/92±10 | 126±15*/74±11* |
| “No Phone Calls” (n = 119) | 156±13/91±10 | 127±16*/73±12* |
| “Phone Calls” (n = 60) | 154±11/92±9 | 125±11*/73±10* |
| Complicated (n = 175) | 163±24/102±20 | 131±19*/78±14* |
| “Traditional” Treatment (n = 86) | 164±24/102±21 | 132±21*/77±16* |
| “Current” Treatment (n = 89) | 161±23/102±19 | 130±18*/78±12* |
| “No Phone Calls” (n = 127) | 162±23/102±19 | 132±20*/79±15* |
| “Phone Calls” (n = 48) | 163±25/103±22 | 127±18*/75±11* |
Data are shown as mean±s.d.; *p< 0.00001 – Randomization Visit versus Final Visit.
Figure 1IASH 2009 How to avoid discontinuation of antihypertensive treatment: the experience in São Paulo, Brazil.- IASH 2009 How to avoid discontinuation of antihypertensive treatment: the experience in São Paulo, Brazil.
Percentage of patients with controlled blood pressure at the beginning (randomization visit), at the next-to-last visit (visit 7) and at the end (visit 8-final) of the 12-month treatment period.
| Group | Randomization Visit | Visit 7 | Final Visit |
| “Uncomplicated” | 0*/0** | 90*/31 | 80/30 |
| “Complicated” | 16/6 | 66/31 | 67/28 |
| “Traditional” Treatment | 8/3 | 75/32 | 73/31 |
| “Current” Treatment | 11/3 | 81/30 | 74/27 |
| “Phone Calls” | 8/3 | 84/32 | 80/33 |
| “No Phone Calls” | 8/3 | 75/30 | 71/27 |
| Total | 8/3 | 78/31 | 74/29 |
Controlled blood pressure: < 140/90 mmHg/120/80 mmHg.
p >0.05, except:
*Uncomplicated versus complicated: Randomization visit - χ21 = 28.94; p<0.000001 (SBP<140/DBP<90)
**Uncomplicated versus complicated: Randomization visit - χ21 = 8.55; p = 0.0035 (SBP<120/DBP<80)
Uncomplicated versus complicated: Visit 7 - χ21 = 28.84; p<0.000001 (SBP<140/DBP<90)
Number of antihypertensive medications in use at the end of the study in patients who achieved control (<140/90 mmHg) of their blood pressure at the end of the 12-month study.
| Number of Antihypertensive Medications | Blood Pressure <140/90 mmHg | Blood Pressure >140/90 mmHg | Total |
| 01 | 3.2% | 1.0% | 4.2% |
| 02 | 34.4% | 5.0% | 39.4% |
| 03 | 21.9% | 6.8% | 28.7% |
| 04 | 12.2% | 6.8% | 19.0% |
| 05 | 3.9% | 2.9% | 6.8% |
| 06 | 1.6% | 0.3% | 1.9% |
| Total | 77.2% | 22.8% | 100% |
Figure 2Discontinuation of antihypertensive treatment.- Discontinuation of antihypertensive treatment.
Weight (kg) at the beginning and end of the treatment.
| Group | Randomization Visit | Final Visit | P Value |
| “Uncomplicated” | 72±12 | 73±13 | 0.39 |
| “Complicated” | 74±15 | 76±15 | 0.007 |
| “Traditional” Treatment | 74±15 | 74±15 | 0.09 |
| “Current” Treatment | 73±13 | 74±13 | 0.005 |
| “Phone Calls” | 74±14 | 74±15 | 0.13 |
| “No Phone Calls” | 73±14 | 74±14 | 0.018 |
| Total | 73±14 | 74±14 | 0.0008 |
Data are shown as mean±s.d.
Results of laboratory tests measured at the beginning and end of the study.
| Initial | Final | Test value | P value | |
| Fasting Glucose (mg/dL) | 108±41 | 111±41 | 1.82 | >0.05 |
| Urea (mg/dL) | 32±10 | 34±16 | 3.83 | = 0.00015 |
| Creatinine (mg/dl) | 0.9±0.3 | 1.0±0.4 | 5.52 | <0.000001 |
| Total Cholesterol (mg/dL) | 199±44 | 190±38 | 5.07 | = 0.000001 |
| HDL Cholesterol (mg/dL) | 49±13 | 48±14 | 1.19 | >0.05 |
| Triglycerides (mg/dL) | 147±123 | 152±218 | 0.61 | >0.05 |
| Uric Acid (mg/dL) | 5.1±1.5 | 5.3±1.8 | 3.90 | = 0.00011 |
| Sodium (mEq/L) | 140±3.2 | 139±2.7 | 7.34 | <0.000001 |
| Potassium (mEq/L) | 4.2±0.5 | 4.2±0.4 | 1.21 | >0.05 |
| Hemoglobin (g/dL) | 14.4±1.4 | 14.2±1.3 | 4.73 | = 0.000003 |
| Alkaline Phosphatase (U/L) | 79.7±25.3 | 75.1±22.7 | 5.29 | <0.000001 |
| ALT (U/L) | 23.5±10.6 | 26.6±51.0 | 1.15 | >0.05 |
| AST (U/L) | 24.4±15.9 | 30.2±92.5 | 1.18 | >0.05 |
| Sodium Urinary Excretion in 24 h (mEq/L) | 119.6±45.6 | 128.8±45.3 | 12.81 | = 0.000036 |
Data are shown as mean±s.d.